Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Residues Involved in the Antigenic Sites of Transmissible Gastroenteritis Coronavirus S Glycoprotein

FÁTIMA GEBAUER,* WILLEM P. A. POSTHUMUS,† ISABEL CORREA,* CARLOS SUÑÉ,* CRISTIAN SMERDOU,* CARLOS M. SANCHEZ,* JOHANNES A. LENSTRA,‡ ROB H. MELOEN,† AND LUIS ENJUANES*,†

*Centro de Biología Molecular, CSIC–Universidad Autónoma, Canto Blanco, 28049 Madrid, Spain; †Central Veterinary Institute, P.O. Box 65, 8200 AD Lelystad, The Netherlands; and ‡Institute of Infectious Diseases and Immunology, Veterinary Faculty, State University, P.O. Box 80, 165, 3508 TD Utrecht, The Netherlands

Received December 28, 1990; accepted April 1, 1991

The S glycoprotein of transmissible gastroenteritis virus (TGEV) has been shown to contain four major antigenic sites (A, B, C, and D). Site A is the main inducer of neutralizing antibodies and has been previously subdivided into the three subsites Aa, Ab, and Ac. The residues that contribute to these sites were localized by sequence analysis of 21 mutants that escaped neutralization or binding by TGEV-specific monoclonal antibodies (MAbs), and by epitope scanning (PEPSCAN). Site A contains the residues 538, 591, and 543, which are essential in the formation of subsites Aa, Ab, and Ac, respectively. In addition, mutant 1B.H8 with residue 586 changed had partially altered both subsite Aa and Ab, indicating that these subsites overlap in residue 586; i.e. this residue also is part of site A. The peptide 537-MKSGYGQPIA-547 represents, at least partially, subsite Ac which is highly conserved among coronaviruses. This site is relevant for diagnosis and could be of interest for protection. Other residues contribute to site B (residues 97 and 144), site C (residues 50 and 51), and site D (residue 385). The location of site D is in agreement with PEPSCAN results. Site C can be represented by the peptide 48-H-P/S-N-S-U/E-52 but is not exposed on the surface of native virus. Its accessibility can be modulated by treatment at pH >11 (at 4°C) and temperatures >45°C. Sites A and B are fully dependent on glycosylation for proper folding, while sites C and D are fully or partially independent of glycosylation, respectively. Once the S glycoprotein has been assembled into the virion, the carbohydrate moiety is not essential for the antigenic sites.

INTRODUCTION

Within the Coronaviridae family, transmissible gastroenteritis virus forms an antigenic cluster with feline infectious peritonitis virus (FIPV), feline enteric coronavirus (FECV), canine coronavirus (CCV), and porcine respiratory coronavirus (PRCV) (Sánchez et al., 1990). TGEV has three structural proteins: the spike protein (S), the nucleoprotein (N), and the membrane (M) protein (Spaan et al., 1988, 1990; Enjuanes and Van der Zeijst, 1991). The S protein forms the peplomers of the virus and consists of 1447 or 1449 amino acids, depending on the viral strain (Rasschaert and Laude, 1987; Jacobs et al., 1987; Wesley, 1990; Britton et al., 1990). Several biological activities have been associated with the S protein. (i) It is the major inducer of neutralizing antibodies and is involved in protection (Garwes et al., 1978; Jiménez et al., 1986; Delmas et al., 1986); (ii) it includes the receptor binding site and determines viral tropism (Holmes et al., 1981; Collins et al., 1982; Suñé et al., 1990); (iii) it is involved in pathogenicity (Taguchi and Fleming, 1989); (iv) it may induce cell fusion (Collins et al., 1982; Sturman et al., 1985; DeGroot et al., 1989); and (v) it has hemagglutinating activity (Holmes et al., 1989).

Type-, group-, and interspecies-specific antigenic determinants have been described for the S glycoprotein of TGEV (Sánchez et al., 1990). In this protein, four antigenic sites (A, B, C, and D) have been defined by mutual competition of MAbs. Site A is antigenically dominant and has been divided into three antigenic subsites: Aa, Ab, and Ac (Correa et al., 1988). Three of the antigenic sites overlap with sites described by others (Delmas et al., 1990; Correa et al., 1990). We have focused on the analysis of the different antigenic sites because of their importance in determining the molecular basis of virulence and immunoprotection against TGE.

Previously, we have located these four sites within the 543 N-terminal amino acids of the S protein (Correa et al., 1990). Site D has been analyzed by epitope scanning (PEPSCAN) (Posthumus et al., 1990). In the present study we have: (i) isolated and characterized 21 TGEV mutants, each deficient in one of the antigenic sites; (ii) identified residues involved in each site by determining the nucleotide differences between the wild-type (wt) virus and mutant viruses; (iii) identified...
sequences, by epitope scanning (Geysen et al., 1984), that could represent antigenic sites A and C; and (iv) described the glycosylation dependence and surface exposure of the sites.

MATERIALS AND METHODS

Cells, viruses, and MAbs

TGEV was grown in swine testicle (ST) cells (McClurkin and Norman, 1966). The strain PUR46-CC120-MAD of TGEV (Sánchez et al., 1990) was used to select virus mutants. This strain was cloned five times in our laboratory. The procedure for TGEV neutralization has been described (Correa et al., 1988). The neutralization index was defined as the log_{10} of the ratio of the PFU after incubating the virus in presence of medium or the indicated MAb. The virus was purified as described (Correa et al., 1988) or partially purified from supernatants of infected cultures. In the latter case, partially purified virus was collected when a CPE of 10 to 50% was observed, by clarification at 6 × 10^3 rpm (Sorvall GS3 rotor) for 20 min followed by sedimentation at 25 × 10^3 rpm (Sorvall AH627 rotor) for 1.5 hr at 4°C. Mouse hepatitis virus (MHV) A59 strain (kindly provided by K. Holmes) was grown on 3T3 cells and purified as described (Sánchez et al., 1990).

The characteristics of the MAbs have been previously described (Jiménez et al., 1986; Correa et al., 1988, 1990; Sánchez et al., 1990; Suné et al., 1990).

Selection of MAb resistant (mar) mutants

mar mutants were selected by neutralizing MAbs as described (Jiménez et al., 1986; Correa et al., 1988) (Table 1). After selection, neutralization titers decreased from 4.8 to less than 0.5. With the non-neutralizing MAbs 1 B.H 11 and 1 D.G3, mar mutants were selected via a procedure similar to the one described by Marlin et al. (1985). Briefly, 10^7 PFU of TGEV in 50 μl medium were incubated at room temperature for 30 min with 50 μl of MAb supernatant, followed by the addition of 50 μl of a 1:10 dilution of rabbit anti-mouse immunoglobulins (Cappel) in phosphate-buffered sa-
ANTIGENIC RESIDUES OF TGE CORONAVIRUS S-GLYCOPROTEIN

Fig. 1. Neutralization of TGEV mar mutants by MAbs and amino acid changes responsible for the escape of mar mutants. White, hatched, and black squares represent neutralization index <1, between 1 and 2, and >2, respectively. The amino acid substitutions in the white areas are indicated with the one-letter code.

Selection of MAb nonbinding (manb) mutants

Mutants that escaped binding of MAb 1D.B12 were selected by incubating 10^8 PFU of TGEV in 0.1 ml of medium with 2 μl of ascitic fluid at 37° for 2 hr. After 2 hr of adsorption, unadsorbed virus was washed out and the cells were incubated at 37°. When CPE appeared, supernatant was collected. The whole procedure was repeated a total of five times, and virus was then plated for in situ immunoscreening (see below). Unstained plaques were selected, incubated in the presence of MAbs and the second antibody as described above, and cloned three times.

Antigenic characterization of virus by radioimmunoassay (RIA)

The procedure for the RIA has been previously described (Correa et al., 1988; Sánchez et al., 1990). Optimum amounts of antigen (between 0.2 and 1.0 μg of protein per well) were used in a RIA and in a competitive radioimmunoassay (cRIA).

Epitope scanning

PEPSCAN analysis was performed using all 1439 consecutive overlapping nonapeptides derived from the sequence of the S protein of TGEV (Jacobs et al., 1987; Rasschaert and Laude, 1987). The peptides were synthesized on polyethylene rods and tested as described previously (Geysen et al., 1984; Posthumus et al., 1990). The first peptide consisted of amino acids 1 to 9, the second consisted of amino acids 2 to 10, the third consisted of amino acids 3 to 11, etc. The binding of a MAb to each peptide was tested in an enzyme-linked immunosorbent assay (ELISA) and expressed as the optical absorbance at 405 nm. Ascitic fluid dilutions varied from 1:10^3 to 1:5 × 10^5. Binding was plotted vertically against the sequence position of the N-terminal amino acid of the peptide. Overlapping nona- to dodecapeptides from the region consisting of the residues 533 to 553 and peptides in which each amino acid of the parent sequence 537-MKRSGYGQPIA-547 was consecutively replaced by all 19 other amino acids were synthesized and tested in the same way. The amino acid replacements were plotted in alphabetical order: A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, and Y (Fig. 3B).

DNA and RNA sequencing

DNA purified from the Bluescript–TGEV plasmids and RNA purified from virions were sequenced by oligodeoxynucleotide primer extension and dideoxynucleotide chain termination procedures (Sanger et al., 1977; Zimmern and Kaesberg, 1978). For RNA sequencing primers complementary to the S-gene were used. Sequence data were assembled and analyzed using the computer programs of the Genetics Computer Group (University of Wisconsin).
Fig. 2. Binding of MAbs to TGEV derived *mar* mutants. MAb binding was determined by RIA, with binding to strain PUR46-CC120-MAD of TGEV as reference value (100). The *mar* mutants are named according to the MAb used in their selection. The specificity of the MAbs is named according to Correa et al. (1988). White, hatched, and black squares represent relative binding between 0 to 19, 20 to 40, and 41 to 100, respectively. ND, not determined. MolV, Moloney leukemia virus. MHV, mouse hepatitis virus.

**Determination of the surface exposure of the epitopes by cRIA**

The accessibility of epitopes on the virus surface was determined by cRIA. It was assumed that higher surface exposure of one epitope would provide a higher inhibition of the binding of the MAb specific for this epitope to the solid phase bound virus. TGEV antigen was plated as described above. Hybridoma supernatants of the MAbs (50 μl), at a dilution giving 90% of maximum binding, were added to TGEV coated wells and incubated at 37°C for 30 min in the presence of twofold dilutions of competitor virus. To measure the binding of the MAbs to the solid-phase bound virus 125I-labeled MAb (5 × 10^6 cpm/well; 1 × 10^6 cpm/μl; 1 × 10^7 cpm/μg protein) was added to wells and incubated at 37°C for 1 hr. The radioactivity bound was determined as described for a RIA. A competition curve was generated for each virus sample. The relative exposure of an antigenic site was defined as the percentage of inhibition of binding of a MAb to virus coated wells by a fixed amount of virus in solution (5 μg per well) divided by 10. This value was extrapolated from each competition curve.

**Deglycosylation and glycosylation inhibition**

The S glycoprotein was purified by phase separation using Triton X-114 (Correa et al., 1988). After dissolution the protein (1 μg/20 μl) in 0.1 M sodium acetate,
TABLE 2

| Starting virus | MAb Used for the selection | Isolation frequency*<sup>b</sup> (-log<sub>10</sub>) |
|----------------|----------------------------|---------------------------------|
| Simple PUR 46 | 1E.F9 Aa                    | 5.1                             |
| PUR 46        | 1G.A7 Aa                    | 5.4                             |
| PUR 46        | 1B.H6 Aa                    | 5.6                             |
| PUR 46        | 1B.B1 Aa                    | 5.6                             |
| PUR 46        | 1D.E7 Ab                    | 5.7                             |
| PUR 46        | 1R.R5 Ac                    | 7.3                             |
| PUR 46        | 6A.C3 Ac                    | >9.0                            |
| Double mar 1 G.A7 | 1B.B6 Aa                  | >8.0                            |
| mar 1D.E7 Ab  | 1G.A6 Aa                    | 6.0                             |
| mar 1B.B5 Ac  | 1B.B1 Aa                    | 7.2                             |
| mar 1D.E7 Ab  | 6A.C3 Ac                    | 0.0                             |
| mar 1G.A6 Aa  | 1B.B1 Aa                    | 0.0                             |
| triple mar 1B.B5-1B.B1 | 1D.E7 Ab                | >7.0                            |
| mar 1D.E7 Ab  | 1B.B5 Ac                    | >7.0                            |
| mar 1B.B5-1D.E7 | 6A.C3 Ac               | 0.0                             |
| mar 1B.C1 Aa  | 0.0                          |                                 |
| mar 1B.H6 Aa  | 0.0                          |                                 |
| mar 1G.A7 Aa  | 0.0                          |                                 |

* The antigenic subsites were defined according to Correa et al. (1988).

b The frequency of mar mutant isolation was defined as previously described (Jiménez et al., 1986).

RESULTS

Site A

A collection of 11 single MAb resistant (mar) mutants and 2 double mar (dmאר) mutants has been isolated from the PUR46 strain of TGEV, using MAbs specific for three subsites (Aa, Ab, and Ac) of TGEV S glycoprotein. The nucleotide sequence differences between these mutants and parental virus have been determined by: (i) sequencing the complete S gene cDNA of the PUR46 wt strain and the first 2000 nucleotides of the PUR46 dmאר 1B.B5—1B.B1 cDNA; (ii) direct RNA sequencing of nucleotides from position 1600 to 2000 of all mutants (Table 1); and (iii) direct RNA sequencing of the complete S gene of the mar 1D.E7 mutant. The escape of mar mutants from neutralization by MAbs specific for subsites Aa, Ab, and Ac was associated with amino acid changes in positions 538, 591, and 543, respectively (Table 1 and Fig. 1). Changes in amino acid 586 from Asp to Asn affected both subsites Aa and Ab. All escape mutants selected by MAb 1B.B5 had an additional amino acid change at position 631.

The mar mutants were characterized by neutralization (Fig. 1) and by binding of MAbs (Fig. 2). Mutants selected with site A-specific MAbs, only showed antigenic changes in site A. The mutants selected by the Aa-specific MAbs could be divided into three groups according to their binding pattern (Fig. 2): (i) mar 1E.F9 and 1G.A7; (ii) mar 1G.A6, 1E.H8, 1D.B3, 1B.C1, and 1C.C12; and (iii) mar 1B.H6. The binding patterns correlated well with the amino acid substitutions (Fig. 1). In mar 1B.H6, subsites Aa and Ab were affected. mar 1B.B5 escaped neutralization by MAbs specific for subsite Ac (1B.B5, 1A.H10, and 6A.C3). However, the epitope of 6A.C3 is probably only partially affected since the binding of mar 1B.B5 by MAb 6A.C3 was normal and MAb 6A.C3 neutralized the 1B.B5 mutant at higher concentrations (not shown). In dmאר 1B.B5—1D.E7 mutant, introduction of changes in subsites Ab and Ac also affected subsite Aa (Fig. 2). In dmאר 1B.B5—1B.B1 the accumulation of mutations in subsites Aa and Ac caused a minor alteration in subsite Ab (Fig. 2). The frequency of single mar mutant isolation in site A was generally between 10⁻⁶ to 10⁻⁸ (Table 2). When a second mutation was accumulated in another antigenic subsite, the isolation frequency was generally about 10-fold lower than for the first mutation. When the two first mutations were localized in subsites Ac/Aa or Ab/Aa, it was not possible to select triple mar mutants with changes accumulated in the three antigenic subsites (Table 2). In contrast, the dmאר 1B.B5—
Fig. 3. PEPSCAN analysis of overlapping nonapeptides from the sequence of the TGEV spike protein. A. The binding of the MAb 1A.F10 (diluted 1:5000), specific for subsite Ac of the S protein (Cortes et al., 1988), was measured as the absorbance at 405 nm by ELISA, and was plotted against the sequence position of the N-terminal amino acid of the peptide (1 to 1439). B. Effect of amino acid substitutions in peptide 537-MKRSGYQPIA-547 on the binding by MAb 1A.F10, specific for subsite Ac. Each parental residue in the sequence was consecutively
1D.E7 mutant selected with MAb 1 specific for subsites Ac and Ab behaved like a triple mar mutant in the neutralization assays performed with subsite Aa-specific MAb (Table 2). MAb 1E.F9 neutralized mar 1B.H6 mutant (Fig. 1). Other site Ac-specific MAb did not neutralize mar 1B.H6 mutant, indicating that the epitope recognized by MAb 1E.F9 was different to the other epitopes of subsite Aa.

As an alternative approach, epitope scanning technology was applied to study the amino acids involved in site Ac. Only MAb 1A.F10 (subsite Ac) showed a specific binding pattern with synthetic peptides (Fig. 3A). Two nonapeptides, which included amino acid 543, were recognized by MAb 1A.F10. To improve the observed binding, analysis of the optimum peptide length was performed using nona- to dodecapeptides. Maximum binding was obtained with the undecapeptide 537-MKRSGYGQPIA-547 (results not shown). The essential amino acids in this peptide were determined by studying the recognition of peptides with consecutive replacement of each amino acid in the native sequence by MAb 1A.F10 (Fig. 3B). The essential residues for binding were the first G (position 541), Y (position 542), and the second G (position 543). The R (position 539), S (position 540), Q (position 544), and I (position 546) could be replaced by a few amino acids, indicating that they also contribute to subsite Ac. MAb 1B.B5, 6A.C3, and 1A.F10 recognized antigenic subsite Ac. MAb 1B.B5 and 6A.C3 did not bind to the peptides recognized by MAb 1A.F10 (data not shown), indicating that they are specific for another epitope(s).

Site B

Site B-specific MAb 1 have not neutralized TGEV infectivity (Suñé et al., 1990). Two procedures were used to select mutants in this site. The first method was to select virus variants that did not bind MAb 1D.B12. Three mutants that did not bind MAb 1D.B12 were selected (MAb nonbinding (manb) mutants). Stocks of TGEV PUR46-CC120-MAD were enriched in the manb 1D.B12 variants by binding wt virions with the MAb 1D.B12 and depleting the virus–antibody complexes with S. aureus coated with rabbit anti-mouse immunoglobulins. The manb mutants were detected by an in situ immunoscreening procedure using nitrocellulose filter replicas of infected monolayers, on which plaques were developed (Díez et al., 1989). Both PUR46 wt and PUR46 manb 1D.B12 mutants showed plaques. Only plaques caused by PUR46 wt were stained by MAb 1D.B12, while all plaques were positive with MAb 3B.B6 specific for the N protein (results not shown). This results confirmed that manb 1D.B12 mutants were not recognized by the MAb used in their selection. The second method used was to select mar mutants by neutralizing virus–antibody complexes with a second antibody against mouse immunoglobulins. TGEV was neutralized by site A-specific MAb, but not by the MAb specific for sites B, C (not shown), and D (Table 3). Infectious virus–antibody complexes, made by binding site B- and D-specific MAb to TGEV, were neutralized up to $10^{4.7}$- and $10^{4.8}$-fold, respectively, by adding rabbit anti-mouse immunoglobulins (Table 3). Two escape mutants were isolated with MAb 1B.H11 (site B) by using this approach: mar 1B.H11-1 and mar 1B.H11-2 (Table 4). In contrast, site C-specific MAb did not bind to native virus (see below) and mediated no neutralization by second antibody.

Site B was previously localized within the first 325 N-terminal residues of the S protein (Correa et al., 1990). The sequence differences between the first 1600 nucleotides of the S-gene of TGEV wt and manb 1D.B12 or 1B.H11 escaping mutants were determined by direct RNA sequencing. The three manb and one mar mutant had in common a change in residue 97 from Trp to Leu or Gly (Table 4). A second mutation in residue 76 of manb 1D.B12-1 was not observed in the other two 1D-B12 mutants and probably represented an accompanying mutation. In the second mutant selected with MAb 1B.H11 (mar 1B.H11-2) residue 144 (Ser) was replaced by Leu. This datum indicates that this amino acid is part of site B.

The four mutants with an amino acid substitution at position 97 were recognized neither by MAb 1D.B12 nor by MAb 1B.H11, while the mar 1B.H11-2 mutant, with a change in residue 144, was recognized by MAb 1D.B12 but not by MAb 1B.H11 (Fig. 4). This indicates that the two MAb see different but overlapping epitopes. The binding of MAb 8F.B3, site B-specific, to the five site B-escaping mutants was not affected by the changes in residues 97 and 144, indicating a third epitope within site B.

Site C

To determine which amino acids compose site C, consecutive overlapping nonapeptides derived from the sequence of the spike protein of TGEV (Rasschaert and Laude, 1987; Jacobs et al., 1987) were tested in the PEPSSCAN, as described above. The same two sets replaced by all 20 amino acids and plotted in alphabetical order of the one-letter code. This resulted in 11 sets of 20 peptide analogues for the indicated sequence. The MAb binding (diluted 1:1000) was measured as the absorbance at 405 nm by an ELISA and was plotted vertically. The capital letters below the horizontal axis indicate the parental residues substituted. Boldface lines indicate the peptides with the native sequence. The dots indicate the values showing significant differences with the background.
TABLE 3

Neutralization of TGEV by MAb Alone or with Rabbit Anti-Mouse Immunoglobulins

| MAb | Specificity | Neutralization index<sup>a</sup> | -MAb<sup>b</sup> | +MAb<sup>c</sup> | +rabbit α-mouse IgG<sup>d</sup> |
|-----|-------------|--------------------------------|----------------|----------------|-------------------------------|
|     |             |                               | Antigenic site<sup>b</sup> |                |                               |
| 1E.F9 | S           | A                             | 2.5           | 3.3            |                               |
| 1D.B12 | S           | B                             | <0.3          | 1.0            |                               |
| 1R.H11 | S           | R                             | <0.3          | 1.0            |                               |
| 1D.G3 | S           | D                             | <0.3          | 1.0            |                               |
| 3B.B6 | N           |                               |               | <0.3          | <0.3                          |

<sup>a</sup> Neutralization index, defined as the log<sub>10</sub> of the ratio of the PFU after incubating the virus in the presence of medium or the MAb.

<sup>b</sup> Undiluted supernatants (50 μl) from hybridoma cultures were mixed with one volume of PBS containing 10⁵ PFU of TGEV (PUR46) and 2% FCS. The neutralization assay was performed as described under Materials and Methods.

<sup>c</sup> Neutralization in the presence of a second antibody was performed by incubating the virus at 37°C for 15 min in presence of the MAb, adding 0.5 vol of a dilution of 1:10 of rabbit antiserum specific for mouse immunoglobulins and incubating at 37°C for 15 min.

Site D

Two mar mutants were selected using site D-specific MAb 1D.G3, by neutralizing the virus–antibody complex with a second antibody against mouse immunoglobulins (Table 3). Direct sequencing of an RNA segment (from nucleotide 1000 to 1000) coding for the protein fragment where site D was previously located of nonapeptides were recognized by MAbs 6A.A6 and 5B.H11 (Figs. 5A and 5B). Each nested set had a common core sequence of 49-Pro-Asn-Ser-Asp-52 and 165-Ser-Asn-Ser-Glu-168, respectively (Fig. 5C). Both sequences shared the motif Asn-Ser followed by an acidic residue (Asp or Glu). The binding of the two MAbs to nonapeptides located between positions 49 to 52 was much higher than to the peptides located between residues 165 and 168 (Figs. 5A and 5B).

In competitive RIA at physiological pH and temperature, virus in solution inhibited the binding of site A specific MAbs to virus coated wells, but did not inhibit the binding of site C specific MAbs (Fig. 6). This indicated that site C was not exposed on the surface of native TGEV. Site C becomes exposed when purified TGEV is bound to plastic plates, or after treatment with detergents, since in direct RIA, purified virus binds site C-specific MAbs (Correa et al., 1988, 1990). Site C was also exposed when virions were partially denatured at pHs 11 to 13 (Fig. 6A). This treatment had almost no effect on the relative antigenicity of site A, and caused a 30-fold decrease in virus infectivity (Fig. 6A). Incubation of TGEV at temperatures ranging from 45 to 95°C increased the relative exposure of site C. In contrast, the binding of site A-specific MAbs decreased after incubating at 40°C and was 10-fold lower after heating the virus 5 min at 95°C (Fig. 6B).

Site D

Two mar mutants were selected using site D-specific MAb 1D.G3, by neutralizing the virus–antibody complex with a second antibody against mouse immunoglobulins (Table 3). Direct sequencing of an RNA segment (from nucleotide 1000 to 1000) coding for the protein fragment where site D was previously located.

### TABLE 4

Differences between the S-Genes from TGEV wt and Sites B and D Mutants

| Clone | Antigenic site | In wt<sup>a</sup> | In mutant<sup>a</sup> | Base change | Amino acid change |
|-------|----------------|----------------|----------------|-------------|------------------|
| manb 1D.B12-1 | B | CTT | TTT | 226 | 76 | Leu Phe |
| manb 1D.B12-2 | B | TGG | TGG | 290 | 97 | Trp Leu |
| manb 1D.B12-3 | B | TGG | TGG | 290 | 97 | Trp Leu |
| mar 1B.H11-1 | D | TGG | GGG | 289 | 97 | Trp Gly |
| mar 1B.H11-2 | D | TGG | GGG | 289 | 97 | Trp Gly |
| mar 1D.G3-1 | D | GGT | AGT | 1153 | 385 | Gly Ser |
| mar 1D.G3-2 | D | GGT | AGT | 1153 | 385 | Gly Ser |

<sup>a</sup> Nucleotide sequence differences were determined by direct RNA sequencing of genome segments on which antigenic sites were previously located (Correa et al., 1990).

<sup>b</sup> All the mutants were derived from PUR46-CC120-MAD strain of TGEV (Sánchez et al., 1990).

<sup>c</sup> The MAb nonbinding (manb) mutants were isolated as described in the text by depleting the parental virus stock from virions that bound MAb 1D.B12. S. aureus coated with rabbit anti-mouse immunoglobulins was used to remove the virus–MAb complex.
Glycosylation dependence of the formation of sites A, B, C, and D

The antigenicity of sites A, B, C, and D of the spike protein was tested after partial or complete deglycosylation of the S protein from mature TGEV with endoglycosidase H or protein N-glycosidase F, respectively, and after inhibiting the glycosylation during virus formation with tunicamycin. Endoglycosidase H partially removed carbohydrates on the S protein yielding a glycoprotein of about 170 kDa which was antigenic for MAb specific for all sites (data not shown). Protein–N-glycosidase F removed carbohydrates from SDS-denatured S-protein down to undetectable levels, as determined by labeling the glycoprotein with [3H]glucosamine and autoradiography (results not shown). The deglycosylated S protein was the same size as the apoprotein as determined by SDS–PAGE (Fig. 7A), and was recognized by MAbs specific for sites A, D, C, and D, although sites A and B were less reactive (Fig. 7A).

To study the effect of intracellular glycosylation ST cells were infected with TGEV in the presence of tunicamycin. At a tunicamycin concentration of 5 μg/ml, the glycosylation of the S protein was inhibited completely (results not shown). S protein was not detected in the culture medium. S protein isolated from the intracellular pool formed aggregates, as indicated by its low mobility during SDS–PAGE even after boiling in the presence of 2.5% SDS and 5% 2-mercaptoethanol (Fig. 7B and results not shown). This S-protein was recognized by site C-MAbs and to a lesser extent by site D-specific MAbs. These data indicate that sites C and D are completely or partially independent of glycosylation, respectively. In contrast, MAbs specific for sites A and B did not recognize unglycosilated S protein (even when the electrophoresis was performed in the presence of 0.1% SDS and in the absence of 2-mercaptoethanol) indicating that these sites are fully dependent on glycosylation for proper folding.

DISCUSSION

In this study, the analysis of TGEV mutants selected by MAbs, and PEPSCAN, have contributed to an accurate localization of the antigenic sites A, B, C, and D of the S glycoprotein. Peptides representing antigenic determinants of sites A and C have been defined. In addition, antigenic sites have been characterized in terms of surface exposure and the relative importance of glycosylation.

In order to map residues associated to different antigenic sites, the segments of the S gene coding for the protein regions, where different antigenic sites were previously localized (Correa et al., 1990), have been sequenced in parental and mutant viruses. In addition,
Site A

Site A is located on the surface of TGEV and is dependent on intracellular glycosylation. With one exception all mutants mapping at site A had a single nucleotide difference with the parental virus. This change was most probably responsible for the virus escaping from MAb neutralization. In other viral systems, single nucleotide differences have also been found to be responsible for escape from neutralization (Vandepol et al., 1986; Taniguchi et al., 1988; Wiegers et al., 1990). In the mar 1B.B5 mutant, and in those variants derived from this virus, two nucleotide differences were detected which caused amino acid changes in residues 543 and 631 (Table 1). The change at position 543 is probably responsible for the escape from MAb 1B.B5, since MAb 1A.F10, which maps to the same antigenic subsite, binds peptides including amino acid 543 (Fig. 3 and results not shown). The change affecting residue 631 could be an accompanying mutation, although its contribution to the epitope 1B.D5 cannot be discounted. Site A contains three subsites, Aa, Ab, and Ac, which are sensitive to substitutions on the residues 538, 591, and 543, respectively. In addition, residue 586 affects both subsites Aa and Ab. These data show that site A is complex and that it is formed by residues located in distal segments of the S glycoprotein. This seems to be the most frequent situation in epitopes from other systems studied in detail (site B reported in this manuscript; DiMarchi et al., 1986; Parry et al., 1989; Davies et al., 1988; Posthumus et al., 1990; Wiegers et al., 1990). Although we have defined precise amino acids contributing to the different antigenic sites, the participation of other residues to the antigenicity of the subsites is not excluded.

Peptide 537-MKRSGYGQPIA-547, recognized by MAb 1A.FlO, could represent at least a portion of the antigenic subsite AC. This peptide may be of importance for diagnosis and protection, since epitope 1A.F10 is located in subsite Ac, which is conserved in coronaviruses of three species (Sánchez et al., 1990).

Our data on site A are in agreement with the data of Delmas et al. (1990), who found MAb-selected mutations at positions 549 and 586. A complete demarcation of the complex site A must await elucidation of the three-dimensional structure of the spike protein.

Site B

Site B is dependent on intracellular glycosylation and is complex and conformation-dependent. This site is
ANTIGENIC RESIDUES OF TGE CORONAVIRUS S-GLYCOPROTEIN

Fig. 6. Effect of the pH and temperature on the relative surface exposure of antigenic sites A and C. Purified TGEV was incubated at different pH (at 4°C) (A) or temperature (B). Dilutions of the virus were used to inhibit the binding of site A- (6A.C3) and C (6A.A8)-specific MAbs to TGEV-coated plates (0.25 μg/well) in a cRIA, as described previously (Correa et al., 1988). A binding inhibition curve was obtained for each viral sample after different incubations. The percentage of binding inhibition by 5 μg of virus per well was divided by ten and taken as the relative exposure of the sites. After each treatment the residual infectivity was determined in a plaque assay on ST cells.

formed by at least three epitopes. Two of these epitopes (1D.B12 and 1B.H11) are overlapping, since both include amino acid Trp in their formation. Sequence analysis of mutants indicated that residues 97 and 144 (Table 4) are part of site B. Although site B is conformation dependent, MAbs specific for this site can bind TGEV S-glycoprotein by immunoblotting providing that the samples were not treated with 2-mercaptoethanol. Most probably, renaturation of S protein occurs during the blotting of the protein to nitrocellulose paper. Recently, we used a new approach to characterize conformation-dependent epitopes (Lenstra et al., 1991). Using MAb 1D.B12, we screened a bacterial pEX expression library of hybrid proteins that consist of β-galactosidase and random hexapeptides. Sequencing of antigenic clones revealed the sequence: -ANSRPRWMKL- (bold residues were expressed by the variable insert of the plasmid). This sequence mimics the epitope of MAb 1D.B12 and may be considered a site B-mimotope (Geysen et al., 1984). The three underlined residues are also found in the S protein sequence 102-RQRHNW-96, suggesting that residues 97, 100, and 102 may be part of site R. These residues might have been displayed in a correct spatial conformation, which mimics the native site, by the contiguous residues present in the mimotope. The serine in position 144 also contributes to site B, since it is changed in the mar 1B.H11 mutant (Table 4). It is tempting to speculate that the serine present in the mimotope (–ANSRPRWMKL–) replaces the serine in position 144 of the parental virus.

Site C

Site C is linear and continuous since: (i) it is recognized by MAbs in Western blot analysis after treatment

Fig. 7. Effect of deglycosylation or glycosylation inhibition on the S protein of TGEV analyzed by immunoblotting. A. The binding of MAbs specific for site A (pool of MAbs 1A.F10, 1G.A7, and 6A.C3), site B (pool of MAbs 1D.B12, 1B.H11, and 8F.B3), site C (6A.A8), and site D (1D.G3) in Western blot to the virus (V), or the S protein after incubation in the presence of protein-N-glycosidase F (+) or in its absence (−) (see Materials and Methods) is shown. B shows the binding of the MAb pools described in A, to extracts of ST cells infected with TGEV in the absence (−) or in the presence (+) of tunicamycin. Mr, position of molecular weight markers in kDa. The electrophoresis preceding the Western blot analysis were performed in the absence of 2-mercaptoethanol to avoid the complete denaturation of S protein.
Fig. 8. Summary of the amino acids contributing to the antigenic sites of the S glycoprotein of two clones of the PUR46 strain of TGEV, and of the properties of the antigenic sites. The diagram shows the position of the residues involved in the formation of the antigenic sites of two clones of the PUR46 virus with a common origin (Bohl, 1972). The antigenic sites were defined by competitive binding assays with MAbs and named according to Correa et al. (1988) (PUR46-CC120-MADRID) (a) and Delmas et al. (1987) (PUR46-CC115-PARIS) (e). In the diagram, the residues implicated in the antigenic sites, as derived from sequence differences between parental virus and escape mutants selected with MAbs, or by PEPSCAN analysis (Correa et al., 1990; Delmas et al., 1990; this study) are shown. The properties of the antigenic sites, are deduced from this study (b) or from other publications: (c) Jimenez et al. (1986); Correa et al. (1988); Sufi et al. (1990); Delmas et al. (1986); Delmas et al. (1990); and (d) Sánchez et al. (1990). A site was defined as conserved (+) if at least part of it was present in most of the isolates. Sites with a minor presence or which were completely absent in certain isolates were referred as ± or −.

of the virus with 2.5% SDS and 5% 2-mercaptoethanol (Fig. 7; Correa et al., 1990); (ii) it is represented by synthetic nonapeptides derived from TGEV S-glycoprotein (Fig. 5); (iii) it is present in recombinant products expressed in bacteria, which do not reconstitute the native S protein (Correa et al., 1990); and (iv) it is formed in the absence of glycosylation (Fig. 7). Since nonapeptides with the sequence (-P-P/S-N-S-D-E-V-) are strongly bound by MAbs 5B.H11 and 6A.A6 under denaturing conditions, this peptide can be used as a reporter to control the expression of the spike protein gene or other heterologous genes. In addition, because binding and sequencing studies indicate that site C is not present in the respiratory variants of TGEV (Sánchez et al., 1990); C. M. Sánchez and L. Enjuanes, unpublished results), this peptide could be useful to discriminate serum from TGEV or PRCV infected animals.

The sequence of the linear site C deduced by PEPSCAN (P-P/S-N-S-D-E-V/A) strongly resembles the sequence of the mimotopes P-P/S-N/H-S-D/E-A selected by site C-specific MAbs from the random-sequence expression library (Lenstra et al., 1991, see above). Serine (S) at position 51 is probably the most essential aminoacid of site C, since it is the only residue conserved in the 12 peptides recognized by epitope scanning (Fig. 5) and in six mimotopes (Lenstra et al., 1991).

Site C is not exposed on native virus, as determined by cRlA (Fig. 6). This agrees with: (i) the absence of this site on the surface of TGEV-infected cells, as determined by immunofluorescence or antibody-dependent complement-mediated cell lysis (Laviada et al., 1990), and (ii) the lack of detection of this site by immune-electron microscopy with gold-labeled MAbs (C. Sun & M. V. Nermut, J. L. Carrascosa, and L. Enjuanes, unpublished results). In contrast, the antigenic sites A, B, and D were detected on the surface of infected cells and on whole virions.

Site D

The glycine (G) residue at position 385 was found to be essential for the epitope of site D-specific MAb 1D.G3 (Table 4). The other site D-specific MAb 8D.H8 recognized both mutants selected by MAb 1D.G3 (Fig. 4). Epitope 8D.H8 has previously been localized within the residues 387 to 392 by PEPSCAN analysis (Post-
Antigenic structure of TGEV

Comparison of the residues involved in the antigenic sites of the S glycoprotein of two clones of the PUR46 strain of TGEV (Fig. 8), one clone (PUR46-CC120-MADRID) studied by our group (Correa et al., 1988, 1990; this study) and another clone (PUR46-CC115-PARIS) studied by Delmas et al. (1990) have shown that sites A, B, and D are located within the same regions of the S protein. Site C was only identified by our group, probably because this site is not exposed in native virions.

In vitro tests, using swine testis cells, indicate that antigenic sites A and D are the major inducers of neutralizing antibodies. The residues that contribute to these sites have been conserved in enteric and respiratory strains of TGEV (PUR46-CC120-MADRID, PUR46-CC115-PARIS, PUR46-115-UTRECHT, MIL65, the British isolate FS772/70), and in feline infectious peritonitis virus (based on sequence data: Rasschaert et al., 1987; Jacobs et al., 1987; Wesley, 1990, Britton et al., 1990; F. Gebauer, C. M. Sánchez, and L. Enjuanes, unpublished data). This suggests that these residues must be important for the replication of viruses of the TGEV group (Sánchez et al., 1990). However, they may not be relevant for the protection in vivo against coronaviruses, since antigenic variation would generate the same or similar substitutions to those observed in our mutants. We are currently testing the potential use of the antigenic peptides for diagnosis and protection.

ACKNOWLEDGMENTS

We are grateful to J. A. García, W. Ian Lipkin, and B. Alarcón for critical comments on the manuscript, to I. Palacín, A. Zazo, and R. Uña for his excellent technical assistance. F.G., I.C., C. Buñé, and C. Smerdou, received fellowships from the Spanish Ministry of Education and Science. This investigation was founded by grants from the Consejo Superior de Investigaciones Científicas, Comisión Interministerial de Ciencia y Tecnología, Fundación Ramón Areces, and European Economic Community (Project BAP 0404.E), and by a grant from the NWO Council for Medical and Health Research (Grant 900-515-002).

REFERENCES

BOHL, E. H., GUPTA, R. K. P., OLQUÍN, M. V. F., and SAIF, L. J. (1972). Antibody responses in serum, colostrum and milk of swine after infection or vaccination with transmissible gastroenteritis virus. Infect. Immun. 6, 289–301.

BRITTON, P., and PAGE, K. W. (1990). Sequence of the S-gene from a virulent British field isolate of transmissible gastroenteritis virus. Virus Res. 18, 71–80.

COLLINS, A. R., KNOBLER, R. L., POWELL, H., and BUCHMEIER, M. J. (1982). Monoclonal antibodies to murine hepatitis virus-4 (strain JHM) define the viral glycoprotein responsible for attachment and cell-cell fusion. Virology 115, 358–371.

CORREA, I., GEBAUER, F., BULLIDO, M. J., SURNÉ, C., BAAY, M. F. D., ZWAGGSTR, K. A., POSTHUMUS, W. P. A., LENSTRA, J. A., and ENJUANCES, L. (1990). Localization of antigenic sites of the E2 glycoprotein of transmissible gastroenteritis coronavirus. J. Gen. Virol. 71, 271–279.

CORREA, I., IMÉNEZ, G., SURNÉ, C., BULLIDO, M. I., and ENJUANCES, L. (1988). Antigenic structure of the E2 glycoprotein from transmissible gastroenteritis coronavirus. Virus Res. 10, 77–94.

DAVIES, D. R., SHERIFF, S., and PADDAN, E. A. (1988). Antibody–antigen complexes. J. Biol. Chem. 263, 10,541–10,544.

DE GROOT, R. J., VAN LEEN, R. W., DOLDER, M. J. M., VENNEMA, H., HORDZINIEK, M. C., and SPAAN, W. J. M. (1989). Stably expressed FIPV plenome protein induces cell fusion and elicits neutralizing antibodies in mice. Virology 171, 493–502.

DELMAS, B., GELFI, J., and LAUDE, H. (1986). Antigenic structure of transmissible gastroenteritis virus. II. Domains in the peplomer glycoprotein. J. Gen. Virol. 67, 1405–1418.

DELMAS, B., RASSCHAERT, D., GEUFET, M., GELFI, J., and LAUDE, H. (1990). Four major antigenic sites of the coronavirus transmissible gastroenteritis virus are located on the amino-terminal half of spike glycoprotein S. J. Gen. Virol. 71, 1313–1323.

DÍEZ, J., MATEU, M. G., and DOMINGO, E. (1989). Selection of antigenic variants of foot-and-mouth disease virus in the absence of antibodies, as revealed by an in situ assay. J. Gen. Virol. 70, 3281–3289.

DMARCHI, R., BROOK, G., GALE, C., CRANCKNELL, V., DOEL, T., and MOWAT, N. (1986). A mutation in the R body-coding sequence destroys expression of the killer trait in P. Tetraurelia. Science 232, 639–641.

ENJUANCES, L., and VAN DER ZEIJST, B. (1991). Molecular basis of transmissible gastroenteritis coronavirus (TGEV) epidemyology. In “The Coronaviruses” (H. Fraenkel-Conrat and R. R. Wagner, Eds.). Plenum, New York. In Press.

GARNES, D. J., LUCAS, M. H., HIGGINS, D. A., PKE, B. V., and CARMEN, S. H. (1978). Antigenicity of structural components from porcine transmissible gastroenteritis virus. Vet. Microbiol. 3, 179–190.

GEYSSEN, H. M., MELDEN, R. H., and BARTLING, I. S. (1984). Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid. Proc. Natl. Acad. Sci. USA 81, 3998–4002.

HOLMES, K. V., DOLLER, E. W., and BEMKNE, J. N. (1981). Analysis of the functions of coronavirus glycoproteins by differential inhibition of synthesis with tunicamycin. Arv. Exp. Med. Biol. 142, 133–147.

HOLMES, K. V., WILLAMS, R. K., and STEPHENS, C. B. (1989). Coronavirus Receptors. In “Concepts in Viral Pathogenesis III” (A. L. Notkins and M. B. A. Oldstone, eds.), pp. 106–113. Springer-Verlag, New York.

JACOBS, L., DE GROOT, R., VAN DER ZEIJST, B. A. M., HORZINIEK, M. C., and SPAAN, W. (1987). The nucleotide sequence of the peplomer gene of porcine transmissible gastroenteritis virus.
(TGEV): Comparison with the sequence of the peplomer protein of feline infectious peritonitis virus (FIPV). Virus Res. 8, 363-371.

Jiménez, G., Correa, I., Melgos, M. P., Bullido, M. J., and Enjuanes, L. (1986). Critical epitopes in transmissible gastroenteritis virus neutralization. J. Virol. 60, 131-139.

Laviada, M. D., Viogain, S. P., Moreno, L., Alonso, F., Enjuanes, L., and Escribano, J. M. (1990). Expression of viral transmissible gastroenteritis virus envelope antigens on the surface of infected cells: Epitopes externally exposed. Virus Res. 16, 247-254.

Lenstra, J. A., Erkens, J. H. F., Zwaagstra, K. A., Posthumus, W. P. A., Meloen, R. H., Gebauer, F., Enjuanes, L., and Stanley, K. K. (1991). Selection of mimotopes from a random sequence expression library using monoclonal antibodies against transmissible gastroenteritis coronavirus. J. Immunol., in press.

McClurkin, A. W., and Norman, J. O. (1966). Studies on transmissible gastroenteritis of swine. II. Selected characteristics of a cytopathogenic virus common to five isolates from transmissible gastroenteritis. Can. J. Comp. Vet. Sci. 30, 190-198.

Marlin, S. D., Holland, T. C., Levine, M., and Glorioso, J. C. (1985). Epitopes of herpes simplex virus type 1 glycoprotein gC are clustered in two distinct antigenic sites. J. Virol. 59, 128-136.

Parry, N. R., Barnett, P. V., Oulridge, E. J., Rowlands, D. J., and Brown, F. (1989). Neutralizing epitopes of type O foot-and-mouth virus. II. Mapping three conformational sites with synthetic peptide reagents. J. Gen. Virol. 70, 1493-1503.

Posthumus, W. P. A., Lenstra, J. A., Schaefer, W. M. M., Van Niewstad, A. P., Enjuanes, L., and Meloen, R. (1990). Analysis and simulation of a neutralizing epitope of transmissible gastroenteritis virus. J. Virol. 64, 3304-3309.

Rasschaert, D., and Laude, H. (1987). The predicted primary structure of the peplomer protein E2 of the porcine coronavirus transmissible gastroenteritis virus / Gen Virol. 68, 1883-1900.

Sánchez, C. M., Jiménez, G., Laviada, M. D., Correa, I., Suñé, C., Bullido, M. J., Gebauer, F., Smerdou, C., Callebaut, P., Escribano, J. M., and Enjuanes, L. (1990). Antigenic homology among coronaviruses related to transmissible gastroenteritis virus. Virology 174, 410-417.

Sanger, F., Nicklen, S., and Coulson, A. R. (1977). DNA sequencing with chain-terminating inhibitors. Proc. Natl. Acad. Sci. USA 74, 5463-5467.

Sørensen, W., Cavagna, D., and Horzinek, M. C. (1988). Coronaviruses: Structure and genome expression. J. Gen. Virol. 69, 2939-2952.

Sørensen, W., Cavagna, D., and Horzinek, M. C. (1990). Coronaviruses. In "Immunochemistry of Viruses. II. The Basis for Serodiagnosis and Vaccines" (M. H. V. van Regenmortel and A. R. Neurath, Eds.), pp. 359-379. Elsevier, Amsterdam.

Sturman, L. S., Ricard, C. S., and Holmes, K. V. (1985). Proteolytic cleavage of the E2 glycoprotein of murine coronavirus: Activation of cell-fusing activity of virions by trypsin and separation of two different 90K cleavage fragments. J. Virol. 56, 904-911.

Suñé, C., Jiménez, G., Correa, I., Bullido, M. J., Gebauer, F., Smerdou, C., and Enjuanes, L. (1990). Mechanisms of transmissible gastroenteritis coronavirus neutralization. Virology 177, 555-569.

Taguchi, F., and Fleming, J. C. (1989). Comparison of six different murine coronavirus JHM variants by monoclonal antibodies against the E2 glycoprotein. Virology 169, 223-235.

Taniguchi, K., Hoshino, Y., Nishikawa, K., Green, K. Y., Maloy, W. L., Morita, Y., Urasawa, S., Kapikian, A. Z., Chanock, R. M., and Gorziglia, M. (1988). Cross-reactive and serotype-specific neutralization epitopes on VP7 of human rotavirus: Nucleotide sequence analysis of antigenic mutants selected with monoclonal antibodies. J. Virol. 62, 1870-1874.

Vandepol, S. B., Lefrancois, L., and Holland, J. J. (1986). Sequences of the major antibody binding epitopes of the Indiana serotype of vesicular stomatitis virus. Virology 148, 312-325.

Wesley, R. D. (1990). Nucleotide sequence of the E2-peplomer protein gene and partial nucleotide sequence of the upstream poly-merase gene of transmissible gastroenteritis virus (Miller strain). Adv. Exp. Med. Biol. 276, 301-306.

Wiegars, K., Wetza, K., and Dernick, R. (1990). Molecular basis for linkage of a continuous and discontinuous neutralization epitope on the structural polyprotein VP2 of poliovirus type 1. J. Virol. 64, 1283-1289.

Zimmer, D., and Kaesberg, P. (1978). 3'-Terminal nucleotide sequence of encephalomyocarditis virus RNA determined by reverse transcriptase and chain-terminating inhibitors. Proc. Natl. Acad. Sci. USA 75, 4257-4261.